Changes in pain and insulin-like growth factor 1 in fibromyalgia during exercise: the involvement of cerebrospinal inflammatory factors and neuropeptides

Table 2 Clinical data, IGF-1, and IGFB-3 for Nordic walking group and low-intensity walking group

	Nordic walking			Low-intensity walking			Difference in change between groups at at 15 weeks	Difference in change between groups at at 30 weeks
	Baseline	15 weeks to 0 weeks	30 weeks to 0 weeks	Baseline	15 weeks to 0 weeks	30 weeks to 0 weeks
	Median (range)	Diff median (range) P value^a	Diff median (range) P value^a	Median (range)	Diff median (range) P value^a	Diff median (range) P value^a	P value^b	P value^b
Pain threshold kPa	199.2 (106.2 to 372.3)	-6.6 (-84.6 to 75.6) P = 0.454	13.9 (-109.2 to 94.1) P = 0.278	215.4 (105.9 to 380.5)	-13.7 (-102.1 to 36.8) P = 0.031	-12.8 (-165.2 to 108.5) P = 0.689	P = 0.169	P = 0.339
Pain mm	70.5 (7 to 98)	-0.5 (-40 to 25) P = 0.416	-1 (-39 to 53) P = 0.988	75 (10 to 92)	-7 (-27 to 35) P = 0.067	-4 (-34 to 29) P = 0.218	P = 0.356	P = 0.432
6MWT m	520 (381 to 660)	36.5 (-44 to 164.5) P < 0.001	29.3 (-150.5 to 145) P = 0.006	516 (428 to 656)	8 (-77 to 107) P = 0.183	-2 (-62.5 to 103) P = 0.520	P = 0.033	P = 0.049
IGF-1 ng/ml	4.3 (0 to 15.6)	-0,2 (-11.4 to 28.7) P = 0.300	-0.7 (-12.7 to 1.7) P = 0.019	3.3 (0 to 35.7)	-0.3 (-31.6 to 1.9) P = 0.148	-0.1 (-31.2 to 1.4) P = 0.109	P = 0.795	P = 0.570
IGFB3 ng/ml	1,449.2 (546.6 to 3,288.3)	-57.4 (-1,524.7 to 1,846.6) P = 0.977	291.1 (-1,383.3 to 2,821.8) P = 0.426	1,680.9 (269.5 to 3,274.2)	-33.5 (-1551.7 to 1,198.8) P = 0.881	242 (-1563 to 1,558.2) P = 0.796	P = 0.906	P = 0.872

^aWilcoxon signed rank test. ^bMann-Whitney U test. Median, range (min-max) for baseline, as well as median differences and P values at 15 and 30 weeks, are presented.

ISSN: 1478-6362